Response: Should initial investigations for neoplastic causes of precocious puberty include serum beta-human chorionic gonadotropin and alpha-fetoprotein?

2014 ◽  
Vol 62 (3) ◽  
pp. 546-546
Author(s):  
Susanne Wendt ◽  
Karen Wright ◽  
Wayne L Furman
Keyword(s):  
Chorionic Gonadotropin ◽  
Precocious Puberty ◽  
Human Chorionic Gonadotropin ◽  
Alpha Fetoprotein ◽  
Beta Human Chorionic Gonadotropin

scholarly journals Alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in ectopic pinealoma with precocious puberty

1979 ◽  
Vol 13 (10) ◽  
pp. 1192-1192
Author(s):  
P Stubbe ◽  
A Kohlschütter ◽  
J Vaitukaitis ◽  
A König ◽  
W Beck ◽  
...  
Keyword(s):  
Chorionic Gonadotropin ◽  
Precocious Puberty ◽  
Human Chorionic Gonadotropin ◽  
Alpha Fetoprotein

A 10-year retrospective single-center study of alpha-fetoprotein and beta-human chorionic gonadotropin in Romanian children with (para)gonadal tumors and cysts

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Usiwoma O. Ataikiru ◽  
Emil R. Iacob ◽  
Ingrith Miron ◽  
Calin M. Popoiu ◽  
Eugen S. Boia
Keyword(s):  
Chorionic Gonadotropin ◽  
Human Chorionic Gonadotropin ◽  
Malignant Tumors ◽  
Germ Cell Tumors ◽  
Area Under The Curve ◽  
Alpha Fetoprotein ◽  
Full Potential ◽  
Tumor Type ◽  
Beta Human Chorionic Gonadotropin ◽  
Β Hcg

Abstract Objectives Malignant tumor is a top-ranking cause of pediatric (>1-year) mortality in America and Europe. Among pediatric tumors, germ cell tumors (GCT) and gonadal tumors rank fourth (6%) by the Surveillance, Epidemiology, and End Results (SEER) program (seer.cancer.gov). Continuous research on tumor markers harnesses their full potential in tumor detection and management. We evaluated the effectiveness of beta-human chorionic gonadotropin (β-hCG) and Alpha-fetoprotein (AFP) in Romanian children with (para)gonadal tumors and cysts, determining their accuracy in detecting malignancy, tumor-type, stage, complications, prognosis, and treatment response. Methods A 10-year retrospective study of AFP and β-hCG in 134 children with cysts and (para)gonadal tumors aged one month to 17 years was performed. Results AFP/β-hCG was unelevated in patients with cysts and nonmalignant tumors. Forty-eight/86 patients (43 GCT and 5 non-GCT) with malignant tumors had elevated AFP/β-hCG, 3/48 patients had recurrences, and 25/48 had mixed-GCT (68% had elevated AFP + β-hCG). All 30 patients with Yolk sac tumors (YST) or their components had elevated AFP. Area under the curve, sensitivity and specificity for GCT were: AFP + β-hCG- 0.828, 67.2%, 100%; AFP- 0.813, 64.1%, 100%; and β-hCG- 0.664, 32.8%, 100%. Two patients whose AFP/β-hCG levels remained elevated died. Common mixed-GCT components were YST-80% and embryonal carcinoma-72%. Thirty of 34 metastasis cases were GCT, with 26/34 patients having elevated AFP/β-hCG. Conclusions AFP/β-hCG detects malignant GCT and can determine tumor-type. GCT patients with markedly elevated AFP + β-hCG had poor prognosis, especially if recurrence or metastasis was present. Recurrence is unrelated to elevated AFP/β-hCG. The tumor components and quantity present determine AFP/β-hCG values in mixed-GCT.

Sign in / Sign up

Export Citation Format

Share Document